Eli Lilly faces new test with Medicare GLP-1 Bridge program
Eli Lilly (LLY) investors have been struggling to answer a deceptively straightforward question for the last two years.
How big can the obesity medicine business get?
The answer has already helped produce one of the most powerful growth stories in health care. Lilly's blockbuster drugs Mounjaro and Zepbound helped turn the company into one of the most valuable in the pharmaceutical sector, thanks to investors' hopes that treatment of obesity may turn out to be one of the biggest drug markets ever.
But one big variable remains unanswered even after years of tremendous expansion.
Access.
The problem is not demand. There are millions of sufferers looking for treatment. The larger concern is how many people can actually pay for these therapies in the end.
That's why Medicare's recent decision could be more important than it appears at first glance.
The Centers for Medicare & Medicaid Services, or CMS, has unveiled the Medicare GLP-1 Bridge, a demonstration program that would give qualified Medicare Part D beneficiaries eligibility to specific GLP-1 medications from July 1, 2026, to Dec. 31, 2027.
The announcement is more than a health care policy story.
For investors in Lilly, that may help answer a much bigger question: Will the obesity-drug business end up being even greater than Wall Street now expects?
That's the $12.8 billion question for Eli Lilly.
Medicare GLP-1 Bridge is key part of Eli Lilly's investment thesis
That is why the size of Lilly's obesity-drug business is important to investors.
Mounjaro earned almost $8.7 billion in sales in the first quarter of 2026, with Zepbound accounting for approximately $4.1 billion. Together, the two medications brought in over $12.8 billion in quarterly sales.
Related: Eli Lilly makes surprising retreat from major market
Those data show the growing importance of GLP-1 treatments to Lilly's future.
But investors already know demand is hot. So the most crucial question is whether the addressable market can keep growing.
Many people are unable to get obesity therapies due to constraints in coverage and cost. Insurers, employers, and government health care programs are thus becoming the chief determinants of the market's long-term size.
That reality makes Medicare more than a policy issue, and it's a key part of Lilly's investment thesis.
CMS said the Medicare GLP-1 Bridge will mean qualified beneficiaries get a $50 monthly cost. The administration also said the initiative will be outside the typical Medicare Part D payment flow, using a centralized processor to oversee prior authorization requests, claims adjudication, and pharmacy payments.
Those nuances matter because the government isn't just adding coverage. It is testing a new framework for market expansion to GLP-1.
With more coverage comes a bigger potential market. Yet if patient eligibility is limited, alternative assumptions about future growth may ultimately be questioned.
GLP-1 access via Medicare could mean bigger-than-ever addressable market
The details of the Medicare GLP-1 Bridge matter less than what the program means.
CMS is actively testing a specific obesity-drug access channel.
CMS has identified several Bridge-eligible therapies, including Eli Lilly's Foundayo and Zepbound KwikPen, as well as Novo Nordisk's Wegovy. CMS notably omitted Zepbound's single-dose vial and single-dose pen formulations from the program.
More Health Care:
- If your Medicare plan was canceled, do this now
- Health care costs are the wild card in year-end tax planning
- 22 million Americans hit by ACA health insurance cliff after vote fails
That means the demonstration is immediately relevant to Lilly. More crucially, it gives investors a glimpse of how governments may approach access to obesity drugs in the future.
The Bridge allows CMS to obtain data on utilization, beneficiary participation, and expenditures while increasing access to qualified beneficiaries.
That doesn't sound like a lot. But for investors, it raises one of the biggest unknowns in anticipating obesity drugs.
Wall Street has generally modeled growth on physician adoption, manufacturing expansion and commercial insurance coverage.
Medicare's latest move throws another crucial aspect into the mix: access provided by the government.
Conversely, if regulators become more comfortable in allowing expanded access, analysts may need to reconsider assumptions about the size of the addressable market. That possibility is also why Lilly's $12.8 billion question relies on Medicare more than ever.
Will the GLP-1 Bridge be a major revenue driver for Lilly?
Investors should not assume the Medicare GLP-1 Bridge will be a big revenue driver, since important questions remain.
CMS has not articulated the levels of long-term involvement, potential policy implications, or how the demonstration findings may inform broader Medicare decisions.
The immediate financial hit could be small. The longer-term repercussions could be far bigger, however.
If the Bridge can withstand high patient demand and affordable costs, authorities may have further evidence to justify future access attempts.
That doesn't mean wider Medicare coverage, but it does add a new variable for investors to observe carefully.
Key takeaways: Medicare GLP-1 Bridge
- Program start date of July 1, 2026
- Current demonstration end date of Dec. 31, 2027
- Operating outside the standard Medicare Part D payment system
- Monthly co-pay of $50 for eligible beneficiaries
- Centralized processor for claims and prior authorization
- Approved therapies including Wegovy, Zepbound KwikPen, and Foundayo
- Single-dose vial and single-dose pen versions of Zepbound not eligible
Medicare is no longer a policy backdrop for Lilly investors.
The Bridge program may have limited near-term financial impact, but it gives CMS a mechanism to examine demand, cost, and utilization inside Medicare. If that test impacts wider access decisions, Wall Street may eventually have to reconsider estimates for the obesity-drug industry.
Mounjaro and Zepbound are already racking up more than $12.8 billion in quarterly revenues, and even slight adjustments in access assumptions might be important.
Related: Wall Street sees huge upside as Novo Nordisk backs biotech company
The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
This story was originally published June 8, 2026 at 10:47 AM.